# US 2005/0233469 A1 · Activity-based probes for protein tyrosine phosphatases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233469 A1
- Document ID: US20050233469A1
- Status: Published application
- Kind: A1
- Application number: 11/107,545
- Filed: 2005-04-15
- Published: 2005-10-20
- Earliest claimed: 2004-04-15
- Assignees: Albert Einstein College of Medicine of Yeshiva University
- Inventors: Zhong-Yin Zhang; Sanjai Kumar
- Web page: https://patentgrep.com/patent/US20050233469A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- C07F 9/4056: {Esters of arylalkanephosphonic acids (C07F9/4025 takes precedence)}
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65522: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C12Q 1/42: involving phosphatase
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/575: for cancer
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- Y10T 436/13: Tracers or tags
- Y10T 436/16: Phosphorus containing
- Y10T 436/19: Halogen containing
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Provided are compounds capable of covalently binding to a protein tyrosine phosphatase (PTP). The compounds comprise Formula A: Also provided are compositions comprising one of the above compounds covalently bound to a member of the PTP superfamily, methods of labeling a PTP using the compounds, methods of isolating a PTP from a mixture of proteins using the compounds, methods of evaluating whether a substance is an inhibitor of a PTP using the compounds, methods of evaluating the specificity of an inhibitor of a PTP using the compounds, methods of identifying a PTP involved in a disease in a mammal using the compounds, and methods of diagnosing a disease in a mammal using the compounds.

## Claims

### Claim 1

A compound capable of covalently binding to a protein tyrosine phosphatase (PTP), the compound comprising Formula A:
wherein
Z is a monocyclic, heterocyclic, bicyclic, or tricyclic moiety that is aromatic where the L-R moiety and the phosphonate-containing moiety is covalently attached to Z at the meta or para positions, or are on different aromatic rings of Z;
X is a good leaving group;
R is a reporter moiety, an affinity moiety, or nothing, provided that when R is nothing, the compound comprises a radioactive moiety or an isotopic variant of any atom; and
L is nothing or any moiety that does not cause steric hindrance preventing the compound from binding to the PTP, provided that L also prevents R from causing steric hindrance preventing the compound from binding to the PTP if R can otherwise cause such steric hindrance.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is selected from the group consisting of a halide, an azide, a sulfonate, a tosylate, a carboxylate, an aryloxy carbonyl, an alkyloxy carbonyl, an aryl- or alkyl-carbonate, an imidazolide, a C1-C4 alkoxy, and a C1-C4 aryloxy.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X is a halide.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is Br.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R is a reporter moiety.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the reporter moiety is biotin, a fluorescent moiety, a hapten, a spin label, or a radioactive moiety.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R is an affinity moiety.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R is biotin, an oligo-His moiety, or a hapten.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R is selected from the group consisting of biotin, a fluorescent molecule, an oligo-His moiety, a radioactive moiety, or a hapten.

### Claim 10 (depends on 1)

The compound of claim 1, comprising an isotopic variant of any atom.

### Claim 11 (depends on 1)

The compound of claim 1, wherein L-R is —CH2—NH—R.

### Claim 12 (depends on 1)

The compound of claim 1, wherein L-R is —CH2—NH—C(O)—(CH2)n—NH—R, where n=1-10.

### Claim 13 (depends on 12)

The compound of claim 12, wherein n=5.

### Claim 14 (depends on 1)

The compound of claim 1, consisting of I or II of FIG. 1 or (a) or (b) of FIG. 9.

### Claim 15 (depends on 1)

A composition comprising the compound of claim 1 covalently bound to a member of the PTP superfamily.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the PTP is selected from the group consisting of a PTP1B, a YopH, a SHP1, a SHP2, a MEG2, a PTPX1, a PTPX10, a PEST, a LyPTP, a MEG1, a BDP1, a PTPH1, a PTPD1, a PTPD2, a PTPBAS, a PTPTyp, a CD45, a PTPλ, a LAR, a HePTP, a PTPaD45, a PTPα, a PTPβ, a PTPε, a PTPγ, a PTPζ, and a PTPIA2.

### Claim 17 (depends on 5)

A method of labeling a protein tyrosine phosphatase (PTP), the method comprising combining the PTP with the compound of claim 5 under conditions and for a time sufficient for the PTP to covalently bind to the compound.

### Claim 18 (depends on 17)

The method of claim 17, wherein the PTP is in a cellular extract.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cellular extract comprises more than one member of the PTP superfamily.

### Claim 20 (depends on 18)

The method of claim 18, wherein the cellular extract is from a mammal.

### Claim 21 (depends on 20)

The method of claim 20, wherein the mammal is a human.

### Claim 22 (depends on 20)

The method of claim 20, wherein the mammal has, or is at risk for, a cancer, diabetes, metabolic syndrome, an inflammatory disease, obesity, an infection by an organism that has a PTP, or an autoimmune disease.

### Claim 23 (depends on 17)

The method of claim 17, further comprising quantifying the PTP by quantifying the amount of reporter moiety bound to the PTP.

### Claim 24 (depends on 7)

A method of isolating a PTP from a mixture of proteins, the method comprising
combining the mixture with the compound of claim 7 under conditions and for a time sufficient for the compound to covalently bind to the PTP; then
combining the mixture with a ligand of the affinity moiety; then
washing the ligand to remove proteins that are not bound.

### Claim 25 (depends on 24)

The method of claim 24, wherein the ligand is part of a matrix of a chromatography column.

### Claim 26 (depends on 24)

The method of claim 24, wherein the affinity moiety is a biotin and the ligand is a matrix comprising avidin.

### Claim 27 (depends on 24)

The method of claim 24, further comprising identifying the PTP.

### Claim 28 (depends on 24)

The method of claim 24, further comprising separating the ligand from the affinity moiety.

### Claim 29 (depends on 28)

The method of claim 28, further comprising determining a characteristic of the PTP, the characteristic selected from the group consisting of the mass of the PTP, an at least partial amino acid sequence of the PTP, and a charge characteristic of the PTP.

### Claim 30 (depends on 29)

The method of claim 29, wherein the characteristic is the mass or partial amino acid sequence of the PTP, as determined by mass spectroscopy.

### Claim 31 (depends on 24)

The method of claim 24, wherein the mixture of proteins is a cellular extract.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cellular extract comprises more than one member of the PTP superfamily.

### Claim 33 (depends on 31)

The method of claim 31, wherein the cellular extract is from a mammal.

### Claim 34 (depends on 33)

The method of claim 33, wherein the mammal is a human.

### Claim 35 (depends on 33)

The method of claim 33, wherein the mammal has, or is at risk for, a cancer, diabetes, metabolic syndrome, an inflammatory disease, obesity, an infection by an organism that has a PTP, or an autoimmune disease.

### Claim 36 (depends on 5)

A method of evaluating whether a substance is an inhibitor of a PTP, the method comprising
combining the substance with the PTP and the compound of claim 5; and
determining whether the compound is bound to the PTP,
wherein a reduction in binding of the compound to the PTP indicates that the substance is an inhibitor of the PTP.

### Claim 37 (depends on 36)

The method of claim 36, wherein the compound not bound to the PTP is separated from the compound bound to the PTP before the determining step.

### Claim 38 (depends on 36)

The method of claim 36, wherein the binding of the compound to the PTP is determined using a labeled antibody to the PTP, a labeled antibody to the reporter moiety, a labeled non-antibody ligand of the reporter moiety, measurement of radioactivity of the compound, measurement of a spin label on the compound, or measurement of fluorescence of the compound.

### Claim 39 (depends on 5)

A method of evaluating the specificity of an inhibitor of a PTP, the method comprising
combining the inhibitor with a mixture of PTPs and the compound of claim 5, and
determining whether the compound is bound to each PTP in the mixture,
wherein a reduction in the binding of the compound to a PTP indicates that the inhibitor inhibits that PTP.

### Claim 40 (depends on 39)

The method of claim 39, wherein the compound not bound to the PTP is separated from the compound bound to the PTP before the determining step.

### Claim 41 (depends on 39)

The method of claim 39, wherein the binding of the compound to the PTP is determined using a labeled antibody to the PTP, a labeled antibody to the reporter moiety, a labeled non-antibody ligand of the reporter moiety, measurement of radioactivity of the compound, measurement of a spin label on the compound, or measurement of fluorescence of the compound.

### Claim 42 (depends on 5)

A method of identifying a PTP involved in a disease in a mammal, the method comprising
obtaining a first cellular extract from a mammal that has the disease and obtaining a second cellular extract from a mammal that does not have the disease;
combining each cellular extract with the compound of claim 5; and
assessing PTPs in each cellular extract by assessing the amount of reporter moiety bound to each PTP,
wherein the presence of a greater amount of a PTP in one of the cellular extracts over the other cellular extract indicates that the PTP is involved in the disease.

### Claim 43 (depends on 42)

The method of claim 42, wherein the PTPs in each cellular extract are quantified by quantifying the amount of reporter moiety bound to each PTP.

### Claim 44 (depends on 42)

The method of claim 42, wherein the disease is a cancer, diabetes, metabolic syndrome, an inflammatory disease, obesity, an infection by an organism that has a PTP, or an autoimmune disease.

### Claim 45 (depends on 42)

The method of claim 42, wherein the PTP is characterized.

### Claim 46 (depends on 5)

A method of diagnosing a disease in a mammal, where the disease is characterized by the presence or change in expression of at least one PTP or the presence or change in the expression profile of the PTP superfamily, the method comprising
obtaining a first cellular extract from a mammal that has the disease and obtaining a second cellular extract from a mammal that does not have the disease;
combining each cellular extract with the compound of claim 5; and
identifying any disease-associated PTP from any PTPs bound to the reporter moiety,
wherein, if the presence or quantity of any disease-associated PTP or the expression profile of the PTPs identified is consistent with the presence of the disease, then the diagnosis is that the mammal has the disease.

### Claim 47 (depends on 46)

The method of claim 46, wherein the disease is characterized by a change in an expression profile of more than one member of the PTP superfamily.
